Direct acting antivirals improved significantly the efficacy and safety of treatment for chronic hepatitis C and result in sustained virological response in the majority of patients with HCV-infection. 3D-therapy (ombitasvir/paritaprevir/ribavirin + dasabuvir) is one of the effective antiviral regimens of treatment in patients with HCV genotype 1 infection. According to meta-analysis of 25 studies in real life clinical practice, the average rate of sustained virological response in more than 5000 patients with HCV genotype 1 infection who were treated with 3D-therapy was comparable to that in the clinical trials. The rate of sustained virological response was high both in patients with and without cirrhosis. Furthermore, the efficacy of treatment did not depend on the presence of baseline resistance mutations. The standard duration of 3Dtherapyis12 weeks. However, theGARNETstudyshowedthe high efficacy of 8-week treatment in patients with HCV genotype 1b infection and F0-F2 fibrosis. In this study, sustained virological response was achieved in 98% of patients. 3Dtherapy can be used both in primary and treatment-experienced patients with chronic HCV-infection. The recent trials also confirmed a favorable safety profile of 3D-therapy.
Antiviral treatment. 3D-therapy, ribavirin, chronic hepatitis C.